Follow-Up | Whole cohort N = 159 | Completed recovery N = 61 | Persistent impairment N = 76 | |||
---|---|---|---|---|---|---|
Floor (0) | Ceiling (100) | Floor (0) | Ceiling (100) | Floor (0) | Ceiling (100) | |
PF | 16 (10) | 9 (6) | 0 (0) | 9 (15)* | 16 (21)* | 0 (0) |
RP | 71 (45)* | 35(22)* | 9 (15)* | 27 (45)* | 54 (71)* | 3 (4.0) |
BP | 11 (7) | 52(33)* | 1 (2) | 35 (57)* | 9 (12) | 7 (9.2) |
GH | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
XSFMA-F | 29(18)* | 0(0) | 29 (46) | 0(0) | 0(0) | 0(0) |